Phase II study of neoadjuvant irinotecan, capecitabine, oxaliplatin (IXO) followed by chemoradiotherapy (CRT) using concurrent capecitabine for resectable locally advanced rectal cancer.
Derek J. Jonker
No relevant relationships to disclose
Jean Alfred Maroun
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
Rebecca Ann C Auer
No relevant relationships to disclose
Nirit Yarom
Consultant or Advisory Role - Sanofi
Celia Marginean
No relevant relationships to disclose
Wael Shabana
No relevant relationships to disclose
Jason R. Pantarotto
No relevant relationships to disclose
Timothy R. Asmis
No relevant relationships to disclose
Robin P. Boushey
No relevant relationships to disclose
Rachel Anne Goodwin
Honoraria - Roche; Sanofi
Wayne Kendal
No relevant relationships to disclose
Shaheer Tadros
No relevant relationships to disclose
Laval Jacques Grimard
No relevant relationships to disclose
Husein Moloo
No relevant relationships to disclose
Martin Friedlich
No relevant relationships to disclose
Caryn Bohemier
No relevant relationships to disclose
Horia Marginean
No relevant relationships to disclose